![]() even with a microphone active EMG-81 ^^ c "is not top. Pramp because it does not leave the BIG sound distortion sick. I am guitarist variety since 2004 and currently plays Jackson EMG-60 and EMG-round 81 bridge. ![]() The firm's revenue was up 33.9% compared to the same quarter last year.Volume, presence, gain, bass, middle, treble. Blueprint Medicines had a negative net margin of 304.41% and a negative return on equity of 45.89%. The firm had revenue of $36.55 million during the quarter, compared to analysts' expectations of $37.61 million. The biotechnology company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($2.23) by ($0.45). Blueprint Medicines has a twelve month low of $43.46 and a twelve month high of $117.86.īlueprint Medicines ( NASDAQ:BPMC - Get Rating) last issued its quarterly earnings results on Tuesday, August 2nd. The firm has a market cap of $4.63 billion, a P/E ratio of -6.55 and a beta of 0.78. The company has a 50 day moving average of $62.53 and a 200-day moving average of $60.57. Shares of NASDAQ:BPMC opened at $77.70 on Friday. ![]() According to data from, the company has an average rating of "Moderate Buy" and an average price target of $92.19. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Finally, Stifel Nicolaus increased their price objective on shares of Blueprint Medicines from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, August 18th. Credit Suisse Group upped their price target on shares of Blueprint Medicines from $80.00 to $90.00 in a research note on Wednesday. Piper Sandler dropped their price objective on shares of Blueprint Medicines from $65.00 to $59.00 in a research report on Tuesday, August 2nd. Oppenheimer increased their target price on shares of Blueprint Medicines from $80.00 to $90.00 and gave the stock an "outperform" rating in a report on Tuesday. The Goldman Sachs Group increased their target price on shares of Blueprint Medicines from $126.00 to $143.00 and gave the stock a "buy" rating in a research report on Wednesday, August 3rd. Morgan Stanley's price target points to a potential upside of 2.96% from the company's previous close.Ī number of other equities research analysts have also recently issued reports on the stock. The firm currently has an "equal weight" rating on the biotechnology company's stock.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |